Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Recent advances in the molecular genetics of type 2 diabetes mellitusGenetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.Obesity and type 2 diabetes: what can be unified and what needs to be individualized?Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach.Locating the source of hyperglycemia: liver versus muscleInsulin resistance in type 2 diabetic youthCoupling of metabolic, second messenger pathways and insulin granule dynamics in pancreatic beta-cells: a computational analysisMethazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo.Writing for publication in a medical journal.Treatment of type 2 diabetes in youth.Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease.Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia.Type 2 diabetes in childhood: clinical characteristics and role of β-cell autoimmunity.Are current clinical trials in diabetes addressing important issues in diabetes care?SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Personalized medicine and type 2 diabetes: lesson from epigenetics.Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy.A Review of Emerging Technologies for the Management of Diabetes Mellitus.The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus.Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.Personalized medicine in Type 2 diabetes: what does the future hold?Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes MellitusIndexing Natural Products for Their Potential Anti-Diabetic Activity: Filtering and Mapping Discriminative Physicochemical Properties.Novel individual metabolic profile characterizes the protein kinase B-alpha (pkbα-/-) in vivo model.Prenatal environmental exposures that may influence β-cell function or insulin sensitivity in middle age.Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes.Precision medicine in diabetes prevention, classification and management.Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
P2860
Q22241288-B34126A2-0985-495F-89B5-8C5F9BC7793FQ26996335-1DF6B651-5CC3-4301-A001-E8942F46922FQ30276113-1EC8B244-B6A1-4007-B283-B3410A818EC3Q30384663-14274C07-F734-4ED9-BF38-3A51ABB08E42Q30501074-AEE751E0-F900-4CB6-8E70-9D69BC7A186BQ33805824-530653EF-69A3-4860-A8F6-573A079698F4Q34522482-DD132076-DA46-49EE-9670-63F7C0ADF655Q34974110-6B1A1176-C28D-4B1B-980F-88878DB9AA00Q35630344-E9F10352-9ABB-4461-BBA9-1B253C520C8FQ36109268-EDE9A6F3-5590-4063-B021-7917D33710E9Q36436489-00EC71DA-18E3-4E80-B1F7-CF3C24A4896DQ36783749-4FA26E7F-18BC-4EFB-BC64-433EF943224DQ37022623-B20D5114-5BC4-472A-890E-DF4AB09A96EEQ37106376-877305F1-CDA0-4BC6-A947-8F5AB730CD93Q37396170-BE95A5CB-AF17-4DD5-BC1E-BCA9D61787E1Q37964530-96E137B6-8157-491D-8199-C5044A9A5368Q38096957-016EB100-B4D7-4E8D-AD47-DCABF28A03F9Q38104746-99A919BA-2606-4C82-AB19-B2E021C7217FQ38210476-688B20CB-3F4D-4F7F-911E-23FEFFE44B49Q38219485-73B137CE-BF1F-4154-B6BF-2E0144524D0CQ38570284-B15648DD-CC45-41E6-91E1-E2686F13A279Q38602464-E35859FC-7CE6-49E5-B936-8FEDE7479740Q38684361-AFFE1E58-0395-4CA1-BD3E-FA225F1388ADQ38918743-C73F1F71-5312-4B2A-BF58-DB8E58D3BC74Q39413300-32B141CF-ED88-427B-B0E5-47A961E69B69Q39624095-BC119370-355C-4C5E-99BF-D92E4149B039Q41607278-AC4AF608-7106-4E19-B5F2-C05A9F6CFBC5Q41934499-0BB5F509-0614-4D0D-951F-BC2A54AAF747Q42217561-4C7D851E-0CD8-451F-90C4-FC0CF7A2A65DQ43560272-641D754C-AA75-4704-B1FC-4404B9CC376BQ50554714-5327F5EE-12F5-45E1-A3E9-94C7EAE1923AQ52677048-CA223FBB-E027-4A6F-A042-95D137279E17Q57412648-EC3405D9-6112-4702-91CC-5A7B19A4A9A2Q58036996-5B17D152-B67F-419A-96C4-CC86EAABEAE1
P2860
Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Individualizing therapies in t ...... know and what we need to know.
@en
Individualizing therapies in t ...... know and what we need to know.
@nl
type
label
Individualizing therapies in t ...... know and what we need to know.
@en
Individualizing therapies in t ...... know and what we need to know.
@nl
prefLabel
Individualizing therapies in t ...... know and what we need to know.
@en
Individualizing therapies in t ...... know and what we need to know.
@nl
P2093
P2860
P356
P1476
Individualizing therapies in t ...... know and what we need to know.
@en
P2093
David M Nathan
Robert A Rizza
Robert J Smith
Silva A Arslanian
P2860
P304
P356
10.1210/JC.2009-1966
P407
P577
2010-03-01T00:00:00Z